Medigene Amends 2022 Financial Guidance
10 Mar 2023
ImmunotherapyPhase 2Financial Statement
Medigene Amends 2022 Financial Guidance
MARTINSRIED, Germany and MUNICH, Germany, March 10, 2023 (GLOBE NEWSWIRE) -- The Executive Management Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today adjusted financial guidance for fiscal year 2022.
The company maintains its guidance on expected revenues to be approximately €30-32 million in 2022.
Research and development costs will increase from prior estimates of €12-14 million to €28-29 million. This is a result of a further write-down of €15.5 million on the drug candidate RhuDex® licensed to Dr. Falk Pharma GmbH, due to the expected termination of the phase 2 clinical study in patients with primary biliary cirrhosis (PBC) by Dr. Falk Pharma.
Estimates for earnings before interest, taxes, depreciation, and amortization (EBITDA) remain unchanged and are expected at € 12-14 million.
The company estimates that it is financed into the fourth quarter of 2024 based on current planning (unchanged).
About Medigene
Medigene AG (FSE: MDG1) is a leading immuno-oncology company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform, built on multiple proprietary and exclusive product enhancement and product development technologies, allows Medigene to create best-in-class differentiated, T Cell Receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com
LifeSci Advisors
Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: svonderweid@lifesciadvisors.com
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.